

NAGASE's Library of Unnatural Amino Acids

Jan. 2017 Ver.23


















NAGASE provides unique α -mono- and α,α -disubstituted unnatural amino acids (UNAA) that can open new avenues for drug development

and accelerate the development of drug candidates in your pipeline

NAGASE UNAAs can be supplied in gram to multi-kg and larger quantities manufactured via stereoselective alkylation of glycine or alanine






NAGASE UNAAs are manufactured without the use of metal catalysts by a safe and environmentally friendly process

NEW PRODUCTS RELEASED





Reactive Amino Acids (α -Alkenyl or α -Alkynyl Glycines and Alanines)



α -AlkenylAla

335438	(S)-α-Allylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.96886-55-4] $C_6H_{11}NO_2 \cdot H_2O = 147.17$	1 g \$ 300
335437	(R)-α-Allylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.96886-56-5] $C_6H_{11}NO_2 \cdot H_2O = 147.17$	1 g \$ 300
		
358028	(S)-N-Fmoc-α-Allylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) [CAS No.288617-71-0] $C_{21}H_{21}NO_4 = 351.40$ Containing 20-50% Methyl <i>tert</i> -butyl ether	(NET) 1 g \$ 900(*)
358027	(R)-N-Fmoc-α-Allylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) [CAS No.288617-76-5] $C_{21}H_{21}NO_4 = 351.40$ Containing 20-50% Methyl <i>tert</i> -butyl ether	(NET) 1 g \$ 900(*)
		
354283	(R)-N-Boc-α-Allylalanine ethyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1263046-12-3] $C_{13}H_{23}NO_4 = 257.33$	1 g \$ 600
		
365023	(S)-N-Fmoc-α-(4-Pentenyl)alanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) [CAS No.288617-73-2] $C_{23}H_{25}NO_4 = 379.46$ Containing 20-50% Methyl <i>tert</i> -butyl ether	(NET) 1 g \$ 800(*) (NET) 5 g \$ 1,800(*)
364440	(R)-N-Fmoc-α-(4-Pentenyl)alanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) [CAS No.288617-77-6] $C_{23}H_{25}NO_4 = 379.46$ Containing 20-50% Methyl <i>tert</i> -butyl ether	(NET) 1 g \$ 800(*) (NET) 5 g \$ 1,800(*)
		
411751	(S)-α-(4-Pentenyl)alanine <i>tert</i>-butyl ester <i>p</i>-Nitrobenzoate ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1323987-70-7] $C_{12}H_{23}NO_2 \cdot C_7H_5NO_4 = 380.44$	1 g \$ 350 5 g \$ 1,400
411752	(R)-α-(4-Pentenyl)alanine <i>tert</i>-butyl ester <i>p</i>-Nitrobenzoate ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1323987-68-3] $C_{12}H_{23}NO_2 \cdot C_7H_5NO_4 = 380.44$	1 g \$ 350 5 g \$ 1,400
		

364441	(S)-N-Fmoc-α-(7-Octenyl)alanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	(NET) 1 g \$ 1,000(*)
	[CAS No.288617-75-4] $C_{26}H_{31}NO_4 = 421.54$	(NET) 5 g \$ 1,900(*)
	Containing 10-40% of Methyl <i>tert</i> -butyl ether	
363955	(R)-N-Fmoc-α-(7-Octenyl)alanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	(NET) 1 g \$ 1,000(*)
	[CAS No.945212-26-0] $C_{26}H_{31}NO_4 = 421.54$	(NET) 5 g \$ 1,900(*)
	Containing 10-40% of Methyl <i>tert</i> -butyl ether	



411915	(S)-α-(7-Octenyl)alanine <i>tert</i>-butyl ester <i>p</i>-Nitrobenzoate ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 700
	[CAS No.1375908-92-1] $C_{15}H_{29}NO_2 \cdot C_7H_5NO_4 = 422.52$	5 g \$ 1,500
388630	(R)-α-(7-Octenyl)alanine <i>tert</i>-butyl ester <i>p</i>-Nitrobenzoate ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 700
	[CAS No.1375904-22-5] $C_{15}H_{29}NO_2 \cdot C_7H_5NO_4 = 422.52$	5 g \$ 1,500



Hydrocarbon-stapling of natural peptides enhances helicity, protease resistance, and cell-permeability as well as improves pharmacologic properties.



C. E. Schafmeister, *et. al. J. Am.Chem.Soc.* **2000**, *122*, 5891-5892.

L. D. Walensky, *et. al. Science* **2004**, *305*, 1466-1470.



Young-Woo Kim *et. al. Org. Lett.* **2010**, *12*, 3046-3049.

α -AlkynylAla



339271	(S)-α-Propargylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 300
	[CAS No.1231709-27-5] $C_6H_9NO_2 = 127.14$	
339270	(R)-α-Propargylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 300
	[CAS No.403519-98-2] $C_6H_9NO_2 = 127.14$	



- 358026 (S)-N-Fmoc- α -Propargylalanine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) (NET) 1 g \$ 800(*)
 [CAS No.1198791-58-0] $C_{21}H_{19}NO_4 = 349.39$
 Containing 20-50% Methyl *tert*-butyl ether
- 358029 (R)-N-Fmoc- α -Propargylalanine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) (NET) 1 g \$ 800(*)
 [CAS No.1198791-65-9] $C_{21}H_{19}NO_4 = 349.39$
 Containing 20-50% Methyl *tert*-butyl ether




- 385412 (S)-N-Fmoc- α -(4-Pentynyl)alanine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) (NET) 1 g \$ 800(*)
 [CAS No.1050501-65-9] $C_{23}H_{23}NO_4 = 377.44$ (NET) 5 g \$ 2,400(*)
 Containing 20-50% Methyl *tert*-butyl ether
- 385411 (R)-N-Fmoc- α -(4-Pentynyl)alanine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) (NET) 1 g \$ 800(*)
 [CAS No.1198791-56-8] $C_{23}H_{23}NO_4 = 377.44$ (NET) 5 g \$ 2,400(*)
 Containing 20-50% Methyl *tert*-butyl ether





- 468736 (R)-N-Fmoc- α -(5-Hexynyl)alanine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) (NET) 1 g \$ 850(*)
 [CAS No.1198791-69-3] $C_{24}H_{25}NO_4 = 391.47$ (NET) 5 g \$ 2,750(*)
 Containing 5-40% of Methyl *tert*-butyl ether

New




α -AlkenylGly


- 345277 (S)- α -Allylglycine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) 5 g \$ 500
 [CAS No.16338-48-0] $C_5H_9NO_2 = 115.13$
- 345276 (R)- α -Allylglycine** ($\geq 98.0\%$, $\geq 98.0\%$ ee) 5 g \$ 500
 [CAS No.54594-06-8] $C_5H_9NO_2 = 115.13$



354273 (R)-N-Acetyl- α -Allylglycine ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 500
 [CAS No.121786-40-1] $C_7H_{11}NO_3 = 157.17$





358025 (S)-N-Boc- α -Allylglycine Dicyclohexylamine salt ($\geq 98.0\%$, $\geq 98.0\%$ ee) 25 g \$ 800
 [CAS No.143979-15-1] $C_{10}H_{17}NO_4 \cdot C_{12}H_{23}N = 396.57$ 100 g \$ 2,500



363068 (S)- α -Allylglycine ethyl ester *p*-Toluenesulfonate ($\geq 97.0\%$, $\geq 98.0\%$ ee) 5 g \$ 200
 [CAS No.1231709-21-9] $C_7H_{13}NO_2 \cdot C_7H_8O_3S = 315.39$ 25 g \$ 800

413726 (R)- α -Allylglycine ethyl ester *p*-Toluenesulfonate ($\geq 97.0\%$, $\geq 98.0\%$ ee) 5 g \$ 200
 [CAS No.1432914-51-6] $C_7H_{13}NO_2 \cdot C_7H_8O_3S = 315.39$ 25 g \$ 800





Application of Allylglycine as the building block for intermediate of pharmaceutical compounds.
 Rutjes, F. P. J. T. *et al. Org. Biomol. Chem.* **2005**, 3, 3435.
 Rutjes, F. P. J. T. *et al. J. Chem. Soc. Perkin Trans. 1*, **2000**, 4197.

α -AlkynylGly

345279 (S)- α -Propargylglycine ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 250
 [CAS No.23235-01-0] $C_5H_7NO_2 = 113.12$

345278 (R)- α -Propargylglycine ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 250
 [CAS No.23235-03-2] $C_5H_7NO_2 = 113.12$




α -Propargyl Amino Acids – Derived Optically Active Novel Substituted Polyacetylenes: Synthesis, Second Structures, and Responsiveness to Ions.
 Sogawa, H. *et al. J. Poly. Sci., Part A: Polym. Chem.* **2012**, 50, 2008.



α,α -DialkenylGly

462304	N-Fmoc-α,α-Bis(4-pentenyl)glycine ($\geq 98.0\%$)	1 g \$ 600
	[CAS No.1068435-19-7] $C_{27}H_{31}NO_4 = 433.55$	5 g \$ 2,400




α -Substituted Alanine derivatives

Alanine (Ala)



328959	(S)-α-Ethylalanine-H_2O ($\geq 98.0\%$, $\geq 98.0\%ee$)	1 g \$ 250
	[CAS No.595-40-4] $C_5H_{11}NO_2 \cdot H_2O = 135.16$	5 g \$ 800

328962	(R)-α-Ethylalanine-H_2O ($\geq 98.0\%$, $\geq 98.0\%ee$)	1 g \$ 250
	[CAS No.3059-97-0] $C_5H_{11}NO_2 \cdot H_2O = 135.16$	5 g \$ 800





358835	(S)-N-Boc-α-Ethylalanine ($\geq 98.0\%$, $\geq 98.0\%ee$)	1 g \$ 300
	[CAS No.151171-11-8] $C_{10}H_{19}NO_4 = 217.27$	5 g \$ 900

395454	(R)-N-Boc-α-Ethylalanine ($\geq 98.0\%$, $\geq 98.0\%ee$)	1 g \$ 300
	[CAS No.123254-58-0] $C_{10}H_{19}NO_4 = 217.27$	5 g \$ 900




354274	(S)-N-Fmoc-α-Ethylalanine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 700(*)
	[CAS No.857478-30-9] $C_{20}H_{21}NO_4 = 339.39$	5 g \$ 1,600(*)


354275	(R)-N-Fmoc-α-Ethylalanine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 700(*)
	[CAS No.1231709-22-0] $C_{20}H_{21}NO_4 = 339.39$	5 g \$ 1,600(*)




472923	(S)-N-Fmoc-α-Methylnorleucine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 700(*)
	$C_{22}H_{25}NO_4 = 367.45$	



467664 (S)-N-Fmoc- α -Methyl- β -*tert*-butylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) 1 g \$ 1,800(*)
 [CAS No.1934266-56-4] $C_{23}H_{27}NO_4 = 381.47$



470629 (S)-N-Fmoc- α -Methylcyclohexylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport) 1 g \$ 700(*)
 [CAS No.1934266-55-3] $C_{25}H_{29}NO_4 = 407.51$





α -Methyl or α -Ethyl derivatives of natural Amino Acids

Aspartic acid (Asp)



346838 (S)- α -Methylaspartic acid ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 400
 [CAS No.3227-17-6] $C_5H_9NO_4 = 147.13$

346839 (R)- α -Methylaspartic acid ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 400
 [CAS No.14603-76-0] $C_5H_9NO_4 = 147.13$





357392 (S)- α -Methylaspartic acid 4-*tert*-butyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 300
 [CAS No.1217977-71-3] $C_9H_{17}NO_4 = 203.24$ 5 g \$ 650

359455 (R)- α -Methylaspartic acid 4-*tert*-butyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 300
 [CAS No.1231709-25-3] $C_9H_{17}NO_4 = 203.24$ 5 g \$ 650





357393 (S)-N-Fmoc- α -Methylaspartic acid 4-*tert*-butyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)
 [CAS No.1072845-47-6] $C_{24}H_{27}NO_6 = 425.48$ (NET) 1 g \$ 800(*)
 Containing $\leq 10\%$ Methyl *tert*-butyl ether (NET) 5 g \$ 1,400(*)

359457 (R)-N-Fmoc- α -Methylaspartic acid 4-*tert*-butyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)
 [CAS No.1231709-26-4] $C_{24}H_{27}NO_6 = 425.48$ (NET) 1 g \$ 800(*)
 Containing $\leq 10\%$ Methyl *tert*-butyl ether (NET) 5 g \$ 1,400(*)





Asparagine (Asn)

412813	(S)-N-Fmoc-α-Methylasparagine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 600
	[CAS No.1403590-49-7] $C_{20}H_{20}N_2O_5 = 368.39$	5 g \$ 1,800
412814	(R)-N-Fmoc-α-Methylasparagine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 600
	[CAS No.1403590-50-0] $C_{20}H_{20}N_2O_5 = 368.39$	5 g \$ 1,800




Cysteine (Cys)

369043	(R)-L-α-Methylcysteine-HCl ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 400
	[CAS No.148766-37-4] $C_4H_9NO_2S \cdot HCl = 171.65$	5 g \$ 1,600
388254	(S)-D-α-Methylcysteine-HCl ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 1,500
	[CAS No.151062-55-4] $C_4H_9NO_2S \cdot HCl = 171.65$	




467668	(R)-L-N-Fmoc-S-Mmt-α-Methylcysteine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	1 g \$ 600(*)
	[CAS No.1198791-74-0] $C_{39}H_{35}NO_5S = 629.77$	5 g \$ 2,400(*)





Glutamine (Glu)

462535	(S)-N-Fmoc-α-Methylglutamic acid 5-<i>tert</i>-butyl ester ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	1 g \$ 900(*)
	[CAS No.1072845-48-7] $C_{25}H_{30}NO_6 = 440.51$	5 g \$ 3,600(*)





Leucine (Leu)



328961	(S)-α-Methylleucine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 250
	[CAS No.105743-53-1] $C_7H_{15}NO_2 = 145.20$	
328960	(R)-α-Methylleucine ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g \$ 250
	[CAS No.29589-03-5] $C_7H_{15}NO_2 = 145.20$	



357394	(S)-N-Fmoc-α-Methylleucine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.312624-65-0] $C_{22}H_{25}NO_4 = 367.45$	
357395	(R)-N-Fmoc-α-Methylleucine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1231709-23-1] $C_{22}H_{25}NO_4 = 367.45$	





465357	(S)-N-Fmoc-α-Ethylleucine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1934266-50-8] $C_{23}H_{27}NO_4 = 381.47$	5 g \$ 2,400(*)
465358	(R)-N-Fmoc-α-Ethylleucine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1934266-51-9] $C_{23}H_{27}NO_4 = 381.47$	5 g \$ 2,400(*)




Lysine (Lys)


369412	(S)-N_α-Fmoc-N_ω-Boc-α-Methyllysine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1202003-49-3] $C_{27}H_{34}N_2O_6 = 482.58$	5 g \$ 2,400(*)
369414	(R)-N_α-Fmoc-N_ω-Boc-α-Methyllysine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1315449-94-5] $C_{27}H_{34}N_2O_6 = 482.58$	5 g \$ 2,400(*)



454268	(S)-N_α-Fmoc-N_ω-Alloc-α-Methyllysine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 1,200(*)
	[CAS No.1934266-47-3] $C_{26}H_{30}N_2O_6 = 466.53$	5 g \$ 4,800(*)





468644	(S)-N_α-Fmoc-N_ω-Mtt-α-Methyllysine ($\geq 98.0\%$, $\geq 98.0\%ee$) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1934266-54-2] $C_{42}H_{42}N_2O_4 = 638.81$	5 g \$ 2,400(*)




Ornithine (Orn)

369026	(S)-N _α -Fmoc-N _ω -Boc-α-Methylornithine (≥ 98.0%, ≥ 98.0%ee) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1315449-95-6] C ₂₆ H ₃₂ N ₂ O ₆ = 468.55	5 g \$ 2,000(*)
369413	(R)-N _α -Fmoc-N _ω -Boc-α-Methylornithine(≥ 98.0%, ≥ 98.0%ee) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.171860-40-5] C ₂₆ H ₃₂ N ₂ O ₆ = 468.55	5 g \$ 2,000(*)





467089	(S)-N _α -Fmoc-N _ω -Mtt-α-Methylornithine (≥ 98.0%, ≥ 98.0%ee) (refrigerated transport)	1 g \$ 800(*)
	[CAS No.1934266-52-0] C ₄₁ H ₄₀ N ₂ O ₄ = 624.78	5 g \$ 2,000(*)





Phenylalanine (Phe)

Substituted benzene ring derivatives are shown in pp. 13-15

322901	(S)-α-Methylphenylalanine·H ₂ O (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.23239-35-2] C ₁₀ H ₁₃ NO ₂ · H ₂ O = 197.23	5 g \$ 900
322898	(R)-α-Methylphenylalanine·H ₂ O (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.17350-84-4] C ₁₀ H ₁₃ NO ₂ · H ₂ O = 197.23	5 g \$ 900





366011	(S)-N-Fmoc-α-Methylphenylalanine·3/2H ₂ O (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.135944-05-7] C ₂₅ H ₂₃ NO ₄ · 3/2H ₂ O = 428.48	5 g \$ 900
366012	(R)-N-Fmoc-α-Methylphenylalanine·3/2H ₂ O (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.152436-04-9] C ₂₅ H ₂₃ NO ₄ · 3/2H ₂ O = 428.48	5 g \$ 900





Proline (Pro)

363402	(S)-N-Boc-α-Methylproline (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 400
	[CAS No. 103336-06-7] C ₁₁ H ₁₉ NO ₄ = 229.28	5 g \$ 1,200
363401	(R)-N-Boc-α-Methylproline (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 400
	[CAS No. 166170-15-6] C ₁₁ H ₁₉ NO ₄ = 229.28	5 g \$ 1,200




386844	(S)-N-Fmoc-α-Methylproline ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g	\$ 500
	[CAS No.167275-47-0] $C_{21}H_{21}NO_4 = 351.40$	5 g	\$ 1,500
386843	(R)-N-Fmoc-α-Methylproline ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g	\$ 500
	[CAS No.1286768-33-9] $C_{21}H_{21}NO_4 = 351.40$	5 g	\$ 1,500





Serine (Ser)

471548	(S)-N-Fmoc-O-<i>tert</i>-Butyl-α-Methylserine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	1 g	\$ 850(*)
	[CAS No.914399-98-7] $C_{23}H_{27}NO_5 = 397.47$	5 g	\$ 2,550(*)





Tryptophan (Trp)

350920	(S)-α-Methyltryptophan-1/2H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g	\$ 700
	[CAS No.16709-25-4] $C_{12}H_{14}N_2O_2 \cdot 1/2H_2O = 227.26$		
350921	(R)-α-Methyltryptophan-1/2H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)	1 g	\$ 700
	[CAS No.56452-52-9] $C_{12}H_{14}N_2O_2 \cdot 1/2H_2O = 227.26$		



359456	(S)-N-Fmoc-N'-Boc-α-Methyltryptophan ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	(NET) 200 mg	\$ 800(*)
	[CAS No.1315449-98-9] $C_{32}H_{32}N_2O_6 = 540.62$	(NET) 1 g	\$ 1,200(*)
	Containing 5% <i>n</i> -Heptane		
365299	(R)-N-Fmoc-N'-Boc-α-Methyltryptophan ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)	(NET) 200 mg	\$ 800(*)
	[CAS No.220155-72-6] $C_{32}H_{32}N_2O_6 = 540.62$	(NET) 1 g	\$ 1,200(*)
	Containing 5% <i>n</i> -Heptane		



Boyle, S. *et al.* *Bioorganic & Medicinal Chemistry* **1994**, 2, 357.
 van Megen, H. J. *et al.* *Psychopharmacology (Berlin)* **1997**, 129, 243.
 Dethlof, L. A. *et al.* *Food Chem. Toxicol.* **1998**, 36, 61.
 Valerie, A. *et al.* *J. Med. Chem.* **2001**, 44, 2276.



Tyrosine (Tyr)

339269 (S)- α -Methyl-4-hydroxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 250

(S)- α -Methyltyrosine

[CAS No.672-87-7]



C₁₀H₁₃NO₃ = 195.22

339268 (R)- α -Methyl-4-hydroxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) 1 g \$ 250

(R)- α -Methyltyrosine

[CAS No.672-86-6]

C₁₀H₁₃NO₃ = 195.22



468643 (S)-N-Fmoc- α -Methyl-4-benzyloxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)

(S)-N-Fmoc-O-Benzyl- α -Methyltyrosine


[CAS No.1283766-46-0]

C₃₂H₂₉NO₅ = 507.59

1 g \$ 500(*)

5 g \$ 2,000(*)

New



468642 (S)-N-Fmoc- α -Methyl-4-hydroxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)

(S)-N-Fmoc- α -Methyltyrosine


[CAS No.246539-83-3]

C₂₅H₂₃NO₅ = 417.46

1 g \$ 500(*)

5 g \$ 2,000(*)

New



467091 (S)-N-Fmoc- α -Methyl-4-triphenylmethoxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) (refrigerated transport)

(S)-N-Fmoc-O-Trityl- α -Methyltyrosine


[CAS No.1934266-53-1]

C₄₄H₃₇NO₅ = 659.78

1 g \$ 800(*)

5 g \$ 3,200(*)

New




387902 (R)-3-Hydroxyphenylalanine (≥ 98.0%, ≥ 98.0%ee) 1 g \$ 500

(R)-*m*-Tyrosine

[CAS No.32140-49-1]

C₉H₁₁NO₃ = 181.19




387901 (R)-3-Methoxyphenylalanine·H₂O (≥ 98.0%, ≥ 98.0%ee) 1 g \$ 700

(R)-*O*-Methyl-*m*-tyrosine

[CAS No.145306-65-6]

C₁₀H₁₃NO₃·H₂O = 213.23



Valine (Val)

333444 (S)- α -Methylvaline (≥ 98.0%, ≥ 98.0%ee) 1 g \$ 300



[CAS No.53940-83-3]

C₆H₁₃NO₂ = 131.18

333443 (R)- α -Methylvaline (≥ 98.0%, ≥ 98.0%ee) 1 g \$ 300

[CAS No.53940-82-2]

C₆H₁₃NO₂ = 131.18



358030 (S)-N-Fmoc- α -Methylvaline (≥ 98.0%, ≥ 98.0%ee) (refrigerated transport) (NET) 1 g \$ 800(*)

[CAS No.169566-81-8]

C₂₁H₂₃NO₄ = 353.42



Containing ≤10% Methyl *tert*-butyl ether

358031 (R)-N-Fmoc- α -Methylvaline (≥ 98.0%, ≥ 98.0%ee) (refrigerated transport) (NET) 1 g \$ 800(*)

[CAS No.616867-28-8]

C₂₁H₂₃NO₄ = 353.42



Containing ≤10% Methyl *tert*-butyl ether





α-Methyl substituted Phenylalanines

F-Phe

410325	(S)-α-Methyl-3-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 400
	[CAS No.130855-56-0] C ₁₀ H ₁₂ FNO ₂ = 197.21	5 g \$ 1,200
411825	(R)-α-Methyl-3-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 400
	[CAS No.1270184-80-9] C ₁₀ H ₁₂ FNO ₂ = 197.21	5 g \$ 1,200
410133	(S)-α-Methyl-4-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.130855-57-1] C ₁₀ H ₁₂ FNO ₂ = 197.21	5 g \$ 900
410132	(R)-α-Methyl-4-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No. 422568-68-1] C ₁₀ H ₁₂ FNO ₂ = 197.21	5 g \$ 900




365442	(S)-N-Fmoc-α-Methyl-2-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.1172127-44-4] C ₂₅ H ₂₂ FNO ₄ = 419.45	
364680	(R)-N-Fmoc-α-Methyl-2-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 300
	[CAS No.1315449-93-4] C ₂₅ H ₂₂ FNO ₄ = 419.45	




468735	(S)-N-Fmoc-α-Methyl-3-fluorophenylalanine (≥ 98.0%, ≥ 98.0%ee) (refrigerated transport)	1 g \$ 500(*)
	[CAS No.1410792-22-1] C ₂₅ H ₂₂ FNO ₄ = 419.45	

New




386761	(S)-N-Fmoc-α-Methyl-2,6-difluorophenylalanine (≥ 98.0%, ≥ 98.0%ee)	1 g \$ 400
	[CAS No.1223105-51-8] C ₂₅ H ₂₁ F ₂ NO ₄ = 437.44	





Mapelli C. *et. al. J. Med. Chem.* **2009**, *52*, 7788-7799.

387097 (R)- α -Methyl-4-trifluoromethylphenylalanine ethyl ester·HCl·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1315449-99-0] C₁₃H₁₆F₃NO₂·HCl·H₂O = 329.75 1 g \$ 600



411843 (S)- α -Methyl-4-trifluoromethoxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No. 1269926-90-0] C₁₁H₁₂F₃NO₃ = 263.22 1 g \$ 800
 5 g \$ 3,200

410538 (R)- α -Methyl-4-trifluoromethoxyphenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1269835-58-6] C₁₁H₁₂F₃NO₃ = 263.22 1 g \$ 800
 5 g \$ 3,200



Br-Phe

322899 (S)- α -Methyl-2-bromophenylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1212180-27-2] C₁₀H₁₂BrNO₂·H₂O = 276.13 1 g \$ 450



322894 (R)- α -Methyl-2-bromophenylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1212307-90-8] C₁₀H₁₂BrNO₂·H₂O = 276.13 1 g \$ 450

328956 (S)- α -Methyl-3-bromophenylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1212117-73-1] C₁₀H₁₂BrNO₂·H₂O = 276.13 1 g \$ 300

328957 (R)- α -Methyl-3-bromophenylalanine·H₂O ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.1212321-90-8] C₁₀H₁₂BrNO₂·H₂O = 276.13 1 g \$ 300



322900 (S)- α -Methyl-4-bromophenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.747397-27-9] C₁₀H₁₂BrNO₂ = 258.11 1 g \$ 400

322897 (R)- α -Methyl-4-bromophenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee)
 [CAS No.752971-41-8] C₁₀H₁₂BrNO₂ = 258.11 1 g \$ 400





I-Phe

329205	(S)- α -Methyl-3-iodophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.457653-01-9] $C_{10}H_{12}INO_2 \cdot H_2O = 323.13$	1 g \$ 350
329207	(R)- α -Methyl-3-iodophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.457652-83-4] $C_{10}H_{12}INO_2 \cdot H_2O = 323.13$	1 g \$ 350
329206	(S)- α -Methyl-4-iodophenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1215092-16-2] $C_{10}H_{12}INO_2 = 305.11$	1 g \$ 300
329204	(R)- α -Methyl-4-iodophenylalanine ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.213203-06-6] $C_{10}H_{12}INO_2 = 305.11$	1 g \$ 300




NO₂-Phe

333075	(S)- α -Methyl-2-nitrophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1241680-71-6] $C_{10}H_{12}N_2O_4 \cdot H_2O = 242.23$	1 g \$ 200
333080	(R)- α -Methyl-2-nitrophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1241680-73-8] $C_{10}H_{12}N_2O_4 \cdot H_2O = 242.23$	1 g \$ 200
333078	(S)- α -Methyl-3-nitrophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1215092-14-0] $C_{10}H_{12}N_2O_4 \cdot H_2O = 242.23$	1 g \$ 200
333076	(R)- α -Methyl-3-nitrophenylalanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No. 1215092-13-9] $C_{10}H_{12}N_2O_4 \cdot H_2O = 242.23$	1 g \$ 200




4-Ph-Phe

335436	(S)- α -Methyl- β -(4-biphenyl)alanine-H ₂ O ($\geq 98.0\%$, $\geq 98.0\%$ ee) [CAS No.1231709-24-2] $C_{16}H_{17}NO_2 \cdot H_2O = 273.33$	1 g \$ 500
--------	--	------------




D-Amino acids**New****Arg**


477449 (R)-Arginine ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 150
 [CAS No.157-06-2] $C_6H_{14}N_4O_2 = 174.20$

**Asn**


477452 (R)-Asparagine-H₂O ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 130
 [CAS No.5794-24-1] $C_4H_8N_2O_3 \cdot H_2O = 150.13$

**Asp**


477473 (R)-Aspartic acid ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 120
 [CAS No.1783-96-6] $C_4H_7NO_4 = 133.10$

**Cys**


477470 (S)-D-Cysteine-HCl-H₂O ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 170
 [CAS No.32443-99-5] $C_3H_7NO_2S \cdot HCl \cdot H_2O = 175.63$

**Glu**

477465 (R)-Glutamic acid ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 130
 [CAS No.6893-26-1] $C_5H_9NO_4 = 147.13$


**Gln**

477466 (R)-Glutamine ($\geq 98.0\%$, $\geq 98.0\%ee$) 25 g \$ 150
 [CAS No.5959-95-5] $C_5H_{10}N_2O_3 = 146.15$




His


477467 (R)-Histidine (≥ 98.0%, ≥ 98.0%ee) 25 g \$ 150
[CAS No.351-50-8] $C_6H_9N_3O_2 = 155.16$

**Lys**


477469 (R)-Lysine·HCl (≥ 98.0%, ≥ 98.0%ee) 25 g \$ 145
[CAS No.7274-88-6] $C_6H_{14}N_2O_2 \cdot HCl = 182.65$

**Met**


477464 (R)-Methionine (≥ 98.0%, ≥ 98.0%ee) 25 g \$ 130
[CAS No.348-67-4] $C_5H_{11}NO_2S = 149.21$

**Phe**

477442 (R)-Phenylalanine (≥ 98.0%, ≥ 98.0%ee) 25 g \$ 135
[CAS No.673-06-3] $C_9H_9NO_2 = 165.19$









**Pro**

477476 (R)-Proline (≥ 98.0%, ≥ 98.0%ee) 25 g \$ 125
[CAS No.344-25-2] $C_5H_9NO_2 = 115.13$



Chemical Abbreviation Definitions

We listed the abbreviations used in this catalog.

Abbreviation	Chemical Name	Chemical Structure
Ac	Acetyl	
Alloc	Allyloxycarbonyl	
Bn	Benzyl	
Boc	<i>tert</i> -Butoxycarbonyl	
Fmoc	9-Fluorenylmethoxycarbonyl	
Mmt	4-Methoxytrityl	
Mtt	4-Methyltrityl	
Trt	Triphenylmethyl Trityl	

Di-Peptides synthesized from our Unnatural Amino Acids

NAGASE is developing a range di-peptides which are composed of a natural amino acid connected to N-terminal of our unnatural, α,α -dialkylated amino acids.




Usually α,α -dialkylated amino acids are not so reactive with other natural amino acids at the N-terminal position because of their steric hindrance around the chiral carbon center.


That is the reason why you may have obtained a peptide in low yield as a result of incomplete conjugation of the amino acid adjacent to the dialkylated amino acid.

As a result NAGASE commissioned certain peptide custom synthesis companies in Japan and China to provide N-Fmoc-protected di-peptide which is composed of a natural amino acid and α,α -dialkylated amino acid and can be used in solid phase peptide synthesis

Examples



Fmoc-Gly-(S)-Ala(4-Pte)-OH



Fmoc-Arg(Pbf)-(S)-Ala(4-Pte)-OH

Application of Unnatural Amino Acids for Pharmaceuticals

Replacement of the α -hydrogen atom of L- α -amino acids with an alkyl substituent results in α,α -disubstituted amino acids has been reported in numerous scientific publications and is seen in APIs and developmental drug candidates. The modification changes the properties of amino acids as follows: 1) increased chemical stability, 2) increased hydrophobicity, 3) restriction of conformational freedom of side chains in amino acids. Incorporation of α,α -disubstituted amino acids into peptides results in the restriction of conformational freedom and increased metabolic stability of the resultant peptides.


Reference:

Tanaka, M. *Chem. Pharm. Bull.* **2007**, *55*, 349-358.

Walensky, L. D.; Kung, A. L.; Escher, I.; Malia, T. J.; Barbuto, S.; Wright, R. D.; Wagner, G.; Verdine, G. L. *Science*, **2004**, *305*, 1466.


Walensky, L. D.; Bird, G. H. *J. Med. Chem.* **2014**, *57*, 6275.

Examples of investigational APIs including α,α -disubstituted amino acids.



Chiral Analogue of Single S1P Receptor


Högenauer, K. *et al. Bioorg. Med. Chem. Lett.* **2010**, *20*, 1485-1487.



Integrin α -2 (LFA-1) Antagonist


LFA-1/ICAM-1 Interaction Inhibitors

Kelly, T.A. *et al. J. Immunol.* **1999**, *163*, 5173-5177.



Glucagon-like Peptide-1 Receptor Agonist with Antidiabetic Activity

Mapelli, C. *et al. J. Med. Chem.* **2009**, *52*, 7788-7799.





NK1 Receptor Antagonist

Boyle, S. *et al. Bioorganic & Medicinal Chemistry* **1994**, *2*, 357-370.

Resistance of a Peptide with α,α -disubstituted Amino Acid against Protease

α -Chymotrypsin Type:VII From Bovine Pancreas



Incubated at 30 °C in 10% DMSO / 0.1 M Pi buffer (pH=8.0) solution


A tryptic digestion assay of an α -methylphenylalanine-containing peptide was carried out to investigate the effect of the replacement of an α,α -dialkylamino acid residue on resistance to protease degradation. The introduction of an α,α -dialkylamino acid residue (α -Methylphenylalanine) to the peptide backbone resulted in greater resistance to protease degradation over 24 hours than the peptide with α -monoalkyl amino acid (phenylalanine). The peptide containing the α,α -dialkylamino acid residue exhibited complete resistance to degradation under the experimental conditions.

Reference:

Matsuyama, K.; Yamamoto, K.; Murakami, S.; Anzai, K. Construction of an unnatural amino acids library through asymmetric alkylation of glycine or alanine ester Schiff-base utilizing Maruoka Catalyst[®].

Presented at the 5th International Peptide Symposium, Kyoto, Japan, December 4-9, 2010; P2-204.

Asymmetric Phase-Transfer Reaction with Maruoka Catalyst[®] to Synthesize α -Monosubstituted and α,α -Disubstituted Amino Acids.



Ikunaka, M. and Maruoka, K. 'Asymmetric Phase-Transfer Catalysts for the Production of Non-Proteinogenic alpha-Amino Acids' in *Asymmetric Catalysis on Industrial Scale 2nd edition*, Blaser, H-U. and Federsel, H.-J. eds. Wiley-VCH Verlag GmbH & Co. KGaA (2010)

According to the Makosza interfacial mechanism, protected α -amino acid is converted into the potassium *E*-enolate. Due to the lipophilic nature of the quaternary ammonium salt it can move easily into the interface layer where cation exchange takes place with the potassium *E*-enolate. As the *si* face of the *E*-enolate is shielded by the molecular cavity of the catalyst, an alkyl halide can only approach the *re* face of the enolate. This results in the Maruoka Catalyst[®] exhibiting high reactivity and selectivity of the alkylation process.

Reference:

- Ooi, T., Kameda, M., and Maruoka, K. *J. Am. Chem. Soc.*, **2003**, 125, 5139-5151.
 Ooi, T., Kameda, M., Tannai, H., and Maruoka, K. *Tetrahedron Lett.*, **2000**, 41, 8339-8342.
 Ooi, T., Takeuchi, M., and Maruoka, K. *Synthesis* **2001**, 1716-1718.
 Maruoka, K. *Org. Process Research & Development* **2008**, 12, 679-687.

Patents:

- USP 6,340,753; 6,441,231; 7,928,224; 8,110,680; 8,252,952; 8,263,798; 8,614,316; 8,697,910; 8,716,524; 8,722,919
 JP 4,217,085; 4,502,293; 4,605,606; 4,802,191; 4,879,896; 5,008,553; 5,108,777; 5,244,149; 5,344,523
 CA 2,549,431; 2,610,776
 SG 139,249; 149,879
 IN 252,017; 260,006
 CN ZL200580003716.6; ZL200680027800.6

Trade mark

Maruoka Catalyst is the registered trade mark in Japan, US, UK, Germany and France.

Sales Information for Unnatural Amino Acids:

Pricing:

All prices are in U.S. dollars. All catalog products are available from inventory in Japan and can be delivered CIP to the designated airport (port of entry) by air within two weeks of confirmed Purchase Order. Prices are subject to change without notice.

Products marked with an asterisk (*) mark may require an additional fee for refrigerated transport.

Ordering:

Orders can be placed by e-mail, phone or fax with the contact person in your region (see Contacts below).

Inquiries:

NAGASE offers a wide range of custom products not listed in this catalog. If you do not find a product you need in this catalog, please inquire about its availability by e-mail, phone or fax. NAGASE will promptly evaluate your request and a NAGASE representative will promptly contact you.

Bulk Quantities & Custom Manufacturing under cGMP:

NAGASE has the technology, experience and capacity to supply bulk and commercial quantities of products as well as custom manufacturing to meet your specific needs. For further information, please contact NAGASE and a technical representative will contact you to discuss your specific project needs.

General Information:

Company Profile: *'a technology and intelligence oriented company that turns wisdom into business.'*

Mission: 'Maintain Good and Fair Business Practice'

NAGASE & CO., LTD., the nucleus of our group, was established as a dyestuffs wholesaler in Kyoto, Japan in 1832. Since then, NAGASE has opened up new markets worldwide together with its customers and accumulated considerable know-how in its role as 'a technology and intelligence oriented trading company.' At the same time, it has enhanced its product offer with new R&D, manufacturing and processing technology. Today, **The NAGASE Group** is a 740 billion JPY (FY 2015) company and offers customers trading, marketing, R&D and manufacturing functions in its four strategic areas of Chemicals, Plastics, Electronics and Life Sciences.

R&D Sites and Nagase Pharmaceutical Group:

NAGASE & CO., LTD. NAGASE R&D CENTER

2-2-3, Murotani, Nishi-ku, Kobe, Hyogo 651-2241 JAPAN

Nagase Medicals Co.,Ltd.

4-323, Senzo, Itami, Hyogo, 664-0898 JAPAN

www.nagase-medicals.co.jp

HAYASHIBARA CO., LTD.

www.hayashibara.co.jp



Contacts!!

New York, US

Nagase America Corporation

546 Fifth Avenue 16th Floor New York, NY 10036-5000 USA

Phone: +1-212-703-1340

Fax: +1-212-398-0687

Rick J. Offerman

e-mail: rickofferman@hotmail.com

Düsseldorf, Germany

Nagase (Europe) GmbH

Immermannstrasse 65c D-40210 Düsseldorf Germany

Phone: +49 211 866 2040 / 2031

Fax: +49 211 323 7068/69

London, UK

Nagase (Europe) GmbH, London Branch

Suite1.02, Winchester House 259-269 Old Marylebone Road London NW1 5RA, UK

Phone: +44-20-7170-4103

Fax: +44-20-7170-4380

Osaka, Japan

NAGASE & CO., LTD. Life & Healthcare Products Department

1-1-17, Shinmachi, Nishi-ku, Osaka 550-8668 JAPAN

Yasumasa Watanabe

e-mail: yasumasa.watanabe@nagase.co.jp

Phone: +81-6-6535-2327

Fax: +81-6-6535-2480

Tokyo, Japan

NAGASE & CO., LTD. Life & Healthcare Products Department

5-1, Nihonbashi-Kobunacho, Chio-ku, Tokyo 103-8355 JAPAN

Phone: +81-3-3665-3840

Fax: +81-3-6535-3940

E-mail: pharma@nagase.co.jp URL: www.nagase.co.jp/pharma/english



Bringing it all together